FRANKFURT, March 9 (Reuters) - Shares in Roche dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...
A phase III trial found that combining giredestrant with Pfizer’s Ibrance did not significantly slow disease progression compared with standard ...
Roche's shares declined sharply after its breast cancer drug, giredestrant, failed a key trial. The drug didn't show meaningful progress when combined with Ibrance. Despite this, analysts see ...
Roche's stock dropped over 5% as its drug giredestrant failed in a trial for breast cancer. The phase III trial didn't show significant progression delay when combined with Pfizer's Ibrance compared ...
A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.
On Thursday, Pfizer Inc. (NYSE:PFE) and Alliance Foundation Trials, LLC (AFT) announced results from the Phase 3 PATINA trial. The trial demonstrated that the addition of IBRANCE (palbociclib) to ...
The second round of Medicare negotiations are here, with the Centers for Medicare and Medicaid (CMS) unveiling the new maximum fair prices for the 15 drugs Tuesday. The list of drugs includes obesity ...
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced the peer-reviewed publication of real-world evidence (RWE) demonstrating that first-line therapy with IBRANCE® (palbociclib) in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results